Cargando…

Rescue of severe brain and cervical cord IRIS by restarting natalizumab in a pregnant MS patient

Detalles Bibliográficos
Autores principales:	Massey, Thomas H., Smith, Rachel, Sadiq, Shaheena, Overton, Christopher, Pearson, Owen R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Clinical/Scientific Notes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5317389/ https://www.ncbi.nlm.nih.gov/pubmed/28077489 http://dx.doi.org/10.1212/WNL.0000000000003604

Ejemplares similares

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc
por: Bsteh, Gabriel, et al.
Publicado: (2017)

VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab
por: Pawlitzki, Marc, et al.
Publicado: (2018)

Incomplete Susac syndrome exacerbated after natalizumab
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2015)

Unusual deterioration in a patient with multiple sclerosis on natalizumab therapy
por: Gattringer, Thomas, et al.
Publicado: (2014)

Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis
por: Frisch, Esther S., et al.
Publicado: (2023)

Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis
por: Hottinger, Andreas F., et al.
Publicado: (2018)

Natalizumab granule cell neuronopathy: FDG-PET in diagnosis and immune reconstitution with G-CSF
por: Kamourieh, Salwa, et al.
Publicado: (2017)

An unusual case of miliary PML-IRIS in an HIV+ patient
por: Cuendet, David, et al.
Publicado: (2017)

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
por: Killestein, J., et al.
Publicado: (2014)

Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions
por: Ventura, Rachel E., et al.
Publicado: (2016)

Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing
por: Rempe, Torge, et al.
Publicado: (2020)

Maraviroc in PML-IRIS: A separate ball game under HIV infection and natalizumab?
por: Steiner, Israel, et al.
Publicado: (2017)

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

Irys Extract
por: Arielly, Rani, et al.
Publicado: (2018)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab
por: Kowarik, Markus C., et al.
Publicado: (2016)

Presence of SARS-CoV-2 Transcripts in the Choroid Plexus of MS and Non-MS Patients With COVID-19
por: Fuchs, Vidmante, et al.
Publicado: (2021)

Natalizumab in the pediatric MS population: results of the Italian registry
por: Ghezzi, Angelo, et al.
Publicado: (2015)

Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab
por: Berkovich, Regina, et al.
Publicado: (2021)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Pathologic Findings of Chronic PML-IRIS in a Patient with Prolonged PML Survival Following Natalizumab Treatment
por: Himedan, Mai, et al.
Publicado: (2017)

IgG4-related hypertrophic pachymeningitis coexpressing antineutrophil cytoplasmic antibodies
por: Massey, Jennifer
Publicado: (2017)

Epstein-Barr–negative MS: a true phenomenon?
por: Dobson, Ruth, et al.
Publicado: (2017)

Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod
por: de Jong, Brigit A., et al.
Publicado: (2018)

Case of alemtuzumab-related alopecia areata management in MS
por: Chan, Jillian K., et al.
Publicado: (2018)

Longitudinally extensive myelitis in MS mimicking neuromyelitis optica
por: Whittam, Daniel, et al.
Publicado: (2017)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2019)

Acute liver injury in a Glatopa-treated patient with MS
por: Sabatino, Joseph J., et al.
Publicado: (2017)

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
por: Novi, Giovanni, et al.
Publicado: (2017)

COVID-19 in MS: Initial observations from the Pacific Northwest
por: Bowen, James D., et al.
Publicado: (2020)

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
por: Antoniol, Caroline, et al.
Publicado: (2015)

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
por: Dong-Si, Tuan, et al.
Publicado: (2014)

Disease activity following pregnancy-related discontinuation of natalizumab in MS
por: Kleerekooper, Iris, et al.
Publicado: (2017)

Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS
por: Gahlen, Anna, et al.
Publicado: (2017)

Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS
por: Largey, Fabienne, et al.
Publicado: (2019)

Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS
por: Scheibe, Franziska, et al.
Publicado: (2018)

Lipoic Acid Pharmacokinetics at Baseline and 1 year in Secondary Progressive MS
por: Bittner, Frank, et al.
Publicado: (2017)

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tuv0allr4gq7qrdbog088lulvq